MucoLife gets Vinnova grant for COPD therapy
MucoLife Therapeutics has been granted SEK 1 million by Vinnova, Sweden’s innovation agency, to scale up manufacturing of MLT-001, its inhaled peptide designed to dissolve mucus plugs in the airways of patients with chronic obstructive pulmonary disease (COPD).
Mucus plugs are present in more than half of patients with moderate-to-severe COPD and are linked to reduced lung function, more exacerbations, and higher mortality. No approved therapy targets them directly.
The Gothenburg-based company has already shown that MLT-001 can be synthesized at scale. Working with a contract development and manufacturing organization (CDMO), it will now develop a purification process with documented yield, along with a process description and control strategy that can later be transferred to Good Manufacturing Practice (GMP) production.
“Manufacturing is the step that turns a promising molecule into a medicine. With Vinnova’s support, we can build the purification process for MLT-001 and move closer to clinical trials,” says Thaher Pelaseyed, CEO of MucoLife.
Published: November 16, 2026
